The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?

Bibliography

• GOODIN DS, FROHMAN EM, GARMANY GP et al.: Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology (2002) 58:169-178.
   PubMed Web of Science ®Google Scholar
• WEINER HL, MACKIN GA, ORAV EJ et al.: Intermirrent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology (1993) 43:910-918.
   PubMed Web of Science ®Google Scholar
• CANADIAN COOPERATIVE MS STUDY GROUP: The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet (1991) 337:441-446.
   PubMed Web of Science ®Google Scholar
• HARTUNG HP, GONSETTE R, KÕNIG N et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind randomized, multicenter trial. Lancet (2002) 360:2018-2025.
   PubMed Web of Science ®Google Scholar
• GONSETTE RE, DEMONTY L: Immunosupression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology (1990) 40:261 (Abstract).
   PubMed Web of Science ®Google Scholar
• GOODIN DS, ARNASON BG, COYLE PK, FROHMAN EM, PATY DW: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 61:1332-1338.
   PubMed Web of Science ®Google Scholar
• BASTIANELLO S, POZILLI C, D’ANDREA F et al.: A controlled trial of mitoxantrone in multiple sclerosis.: serial MRI evaluation at one year. Can. J. Neurol. Sci. (1994) 21:266-270.
   PubMed Web of Science ®Google Scholar
• MAUCH E, EISENMANN S, HAHN A et al.: Mitoxantrone (MITOX) in the treatment of multiple sclerosis (MS): a large single center experience. Proceedings of the 124th Annual Meeting of the American Neurological Association, Seattle, USA (1999) (Abstract).
   Google Scholar
• ETEMADIFAR M, HAMZEHLOO A: Mitoxantrone reduced disability in Iranian patients with multiple sclerosis. Multiple Sclerosis. (Poster abstract 0497A) Presented at The World Congress of Neurology, Sydney, Australia (2005).
   Google Scholar
• LEPAGE E, LERAY E, COUSTANS M, CHAPERON J, EDAN G: Clinical impact of mitoxantrone in 100 consecutive aggressive realapsing-remitting multiple sclerosis patients: a 5 year follow-up observational study. Mult. Scler. (2005) 11(Suppl. 1):S171. (Abstract).
   Google Scholar
• TÉLLEZ N, RÍO J, TINTORI M, ROVIRA Á, NOS C, GALÁN Í et al.: Mitoxabtrone in MS patients, non-responders to interferon. Mult. Scler. (2005) 11(Suppl. 1):S172 (Abstract).
   Web of Science ®Google Scholar
• FOX E, AL-SABBAGH A, BENNETT R, SADIQ S: Safety and tolerability of Novantrone® (mitoxantrone) in clinical practice: Status report from the Registry to evaluate Novantrone® effects in worsening MS (RENEW) study. Neurology (2005) 64(Suppl. 1):A394 (Abstract).
   Google Scholar
• EDAN G, BROCHET B, CLANET M et al.: Safety profile of mitoxantrone in a cohort of 800 multiple sclerosis patients. Mult. Scler. (2001) 7(Suppl. 1):S14 (Abstract).
   Google Scholar
• JEFFERY DR: Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology (2004) 63(Suppl. 6):S41-S46 (Abstract).
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: NOVANTRONE (mitoxantrone) package insert, Immunex Corporation, Seattle (2002).
   Google Scholar
• GONSETTE RE: Mitoxantrone in progressive multiple sclerosis: when and how to treat? J. Neurol. Sci. (2003) 206:203-208.
   PubMed Web of Science ®Google Scholar
• SYED AR, ZWIBEL H, FOX EJ: Mitoxantrone for multiple sclerosis in clinical practice. Neurology (2004) 63(Suppl. 6):S25-S27.
   PubMed Web of Science ®Google Scholar
• GHALIE RG, EDAN G, LAURENT M, MAUCH E et al.: Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology (2002) 59:909-913.
   PubMed Web of Science ®Google Scholar
• POSNER LE, DUKARTG, GOLDBERG J et al.: Mitoxantrone: an overview of safety and toxicity. Invest. New Drugs (1985) 3:123-132.
   PubMed Web of Science ®Google Scholar
• BENJAMIN RS, CHAWLA SP, EWER MS et al.: Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Invest. New Drugs (1985) 3:117-121.
   PubMed Web of Science ®Google Scholar
• BRASSAT D, RECHER C, WAUBANT E et al.: Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology (2002) 59:954-955.
   PubMed Web of Science ®Google Scholar
• VOLTZ R, STARCK M, ZINGLER V, STRUPP M, KOLB H-J: Mitoxantrone therapy in multiple sclerosis and acute leukemia: a case report out of 644 treated patients. Mult. Scler. (2004) 10(4):472-474.
   PubMed Web of Science ®Google Scholar
• FELIX CA: Secondary leukemias induced by topoisomerase-targeted drugs. Biochem. Biophys. Acta (1998) 140:233-255.
   Google Scholar
• LEVINE S, SALTZMAN A: Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J. Neuroimmunol. (1986) 13:175-181.
   PubMed Web of Science ®Google Scholar
• NOSEWORTHY J, HOPKINS MB, VANDERVOORT MK et al.: An open trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology (1993) 43:1401-1406.
   PubMed Web of Science ®Google Scholar
• MILLEFIORINI E, GASPERINI C, POZZILLI C et al.: Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J. Neurol. (1997) 244:153-159
   PubMed Web of Science ®Google Scholar
• HARTUNG HP, GONSETTE R, MORRISSEY S, KRAPF H, FAZEKAS F: Mitoxantrone. In: Rudick RA, Goodkin DE (Eds.), Multiple Sclerosis Therapeutics, London Martin Dunitz, (1999):335-348.
   Google Scholar
• KRAPF H, MORRISSEY SP, ZENKER O, ZWINGERS T, GONSETTE R, HARTUNG HP, AND THE MIMS STUDY GROUP: Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology (2005) 65:690-695.
   PubMed Web of Science ®Google Scholar
• FOX E, RENEW STUDY TEAM: Evaluation of safety and tolerability of mitoxantrone in the continuation of the worsening multiple sclerosis (RENEW) study. Proceeding of the Consortium of MS Centers, Orlando, USA (2005):77.
   Google Scholar
• JEFFERY DR, CHEPURI N, DURDEN D, BURDETTE J: A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult. Scler. (2005) 11(3):296-301.
   PubMed Web of Science ®Google Scholar
• AVASARALA JR, CROSS AH, CLIFFORD DB et al.: Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult. Scler. (2003) 9:59-62
   PubMed Web of Science ®Google Scholar
• ETEMADIFAR M, HAMZEHLOO A: Secondary Amenorrhea associated with mitoxantrone therapy in patients with multiple sclerosis. Presented at The World Congress of Neurology, Sydney, Australia (2005) Poster abstract 0497B.
   Google Scholar
• MACLEAN H, FREEDMAN MS, ATKINS HL et al.: Mitoxantrone therapy in multiple sclerosis Mult. Scler. (2005) 11(Suppl. 1):S171 (Abstract).
   Google Scholar
• KALLWEIT U, RAJDA E, POEHLAU D: Mitoxantrone treatment of secondary progressive multiple sclerosis patients with EDSS > 6. Mult. Scler. (2005) 11(Suppl. 1):S172 (Abstract).
   Google Scholar
• VOLLMER T, CAMPAGNOLO: Symptom control and quality of life following mitoxantrone treatment. Proceedings of Consortium of MS Centers Meeting, Orlando, USA (2005):61.
   Google Scholar
• VOLLMER T, PANITCH H, DUNN S, LUBLIN FD, O’CONNOR PW, BAR-OR A et al.: Induction treatment with mitoxantrone (Novantrone®) preceeding treatment with glatiramer acetate (Copaxone®), a multi-center randomized two-arm, open-label study in RRMS patients. Mult. Scler. (2005) 11(Suppl. 1):S87 (Abstract).
   Google Scholar
• KITA M, CHOW E, DAVID R: A pilot study of mitoxantrone plus dexrazoxane versus mitoxantrone in patients with relapsing remitting, secondary progressive and progressive relapsing MS. Neurology (2005) 64(Suppl 1)A330 (Abstract).
   Web of Science ®Google Scholar
• COHEN BA, JEFFERY DR: Identification of suboptimal responders to immune modulating agents and the role of mitoxantrone in worsening multiple sclerosis. Neurology (2004) 63(12) (Suppl. 6):S1-S2.
   Google Scholar
• SCOTT LJ, FIGGITT DP: Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs (2004)18:379-396.
   PubMed Web of Science ®Google Scholar
• MAO-DRAAYER Y, FILLIPI CG, PANITCH HS. Mitoxantrone treatment effect on lupoid sclerosis is independent of autoantibody levels. Presented at The World Congress of Neurology, Sydney, Australia (2005). Poster abstract 0535.
   Google Scholar
• COHEN BA, MIKOL DD: Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology (2004) 63(Suppl. 6):S28-S32.
   PubMed Web of Science ®Google Scholar
• CAON C, DIN M, MADAK S, TSELIS A, LISAK R, KHAN O: Two year open-label observational study comparing monthly intravenous (IV) cyclophosphamide (CTX) and every three month IV mitoxantrone (MIT) in worsening MS patients. Neurology (2005) 64(Suppl. 1):A329 (Abstract).
   Google Scholar